MT-ATP6 pseudogene 26 (MTATP6P26)

MT-ATP6 pseudogene 26 (MTATP6P26) is annotated as a pseudogene referencing the well-characterized mitochondrially encoded ATP synthase 6 subunit gene (MT-ATP6). Pseudogenes are DNA regions similar to known genes but generally lack the ability to encode functional proteins due to sequence changes such as premature stop codons or frameshift mutations. The functional MT-ATP6 gene encodes a membrane subunit of the mitochondrial ATP synthase complex (Complex V) that is essential for normal oxidative phosphorylation and ATP production within mitochondria[1][3][5][7][8]. In contrast, MTATP6P26 does not contribute to these cellular processes and is not implicated in disease or targeted by drugs. Only the canonical, protein-coding MT-ATP6 gene (not the pseudogene) is associated with mitochondrial disorders such as Leigh syndrome and NARP syndrome[1][3][5][6][7][8]. Additional Clarification: MTATP6P26 is not a recognized therapeutic target, nor does it fulfill criteria for enzyme, transporter, or receptor classification. This name refers specifically to a pseudogene, which is not generally included in target discovery or drug development literature. If information is sought for the canonical "MT-ATP6" gene, which is protein-coding and disease-associated, see the entries for “mitochondrially encoded ATP synthase membrane subunit 6 (MT-ATP6)”. Summary: MTATP6P26 is a pseudogene of mitochondrial ATP synthase 6 and is not an accepted therapeutic target, receptor, enzyme, or biomarker in biology or medicine. It does not have documented biological functions, disease roles, or drug interactions, and its mention represents either a misdirected query or a non-target entity[1][3][5][6][7][8].

Other names

MTATP6P26mitochondrially encoded ATP synthase 6 pseudogene 26